CN1655848A - 新依托孕烯酯的用途 - Google Patents

新依托孕烯酯的用途 Download PDF

Info

Publication number
CN1655848A
CN1655848A CNA038123657A CN03812365A CN1655848A CN 1655848 A CN1655848 A CN 1655848A CN A038123657 A CNA038123657 A CN A038123657A CN 03812365 A CN03812365 A CN 03812365A CN 1655848 A CN1655848 A CN 1655848A
Authority
CN
China
Prior art keywords
etonogestrel
undecanoate
contraceptive
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038123657A
Other languages
English (en)
Chinese (zh)
Inventor
H·德尼因斯
H·A·A·万德福尔特
D·莱森
A·J·格罗滕胡伊斯
J·万德劳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of CN1655848A publication Critical patent/CN1655848A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CNA038123657A 2002-05-30 2003-05-22 新依托孕烯酯的用途 Pending CN1655848A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077118 2002-05-30
EP02077118.4 2002-05-30

Publications (1)

Publication Number Publication Date
CN1655848A true CN1655848A (zh) 2005-08-17

Family

ID=29595013

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038123657A Pending CN1655848A (zh) 2002-05-30 2003-05-22 新依托孕烯酯的用途

Country Status (26)

Country Link
US (1) US20050222114A1 (enExample)
EP (1) EP1513588B1 (enExample)
JP (1) JP2005532336A (enExample)
KR (1) KR20050005507A (enExample)
CN (1) CN1655848A (enExample)
AR (1) AR040129A1 (enExample)
AT (1) ATE394140T1 (enExample)
AU (1) AU2003246740B2 (enExample)
BR (1) BR0311248A (enExample)
CA (1) CA2487293A1 (enExample)
DE (1) DE60320786D1 (enExample)
ES (1) ES2305498T3 (enExample)
HR (1) HRP20041127A2 (enExample)
IL (1) IL165125A0 (enExample)
IS (1) IS7537A (enExample)
MX (1) MXPA04011798A (enExample)
NO (1) NO20044903L (enExample)
NZ (1) NZ536618A (enExample)
PE (1) PE20040042A1 (enExample)
PL (1) PL373295A1 (enExample)
RS (1) RS101004A (enExample)
RU (1) RU2322986C2 (enExample)
TW (1) TW200400041A (enExample)
UA (1) UA80703C2 (enExample)
WO (1) WO2003101374A2 (enExample)
ZA (1) ZA200409498B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1314701C (zh) * 2002-05-30 2007-05-09 欧加农股份有限公司 依托孕烯酯
CN111057120A (zh) * 2019-12-27 2020-04-24 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123523A1 (en) * 2011-11-10 2013-05-16 Klaus Nickisch Methods for the preparation of etonogestrel and desogestrel
DE102012211511A1 (de) * 2012-07-03 2014-01-09 Siemens Aktiengesellschaft Bestimmung der Eignung einer Ressource
BR112020007673A2 (pt) * 2017-10-19 2020-10-13 Evestra, Inc. contraceptivos pró-fármaco de progestina de ação prolongada
EP4164743A2 (en) * 2020-06-11 2023-04-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) * 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) * 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
CN1135716A (zh) * 1993-12-27 1996-11-13 阿克佐诺贝尔公司 经皮吸收的药用制剂
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
TR200003743T2 (tr) * 1998-06-19 2001-07-23 Akzo Nobel N.V. Testosteron türevi.
WO1999067270A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1314701C (zh) * 2002-05-30 2007-05-09 欧加农股份有限公司 依托孕烯酯
CN111057120A (zh) * 2019-12-27 2020-04-24 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Also Published As

Publication number Publication date
NZ536618A (en) 2007-06-29
RU2322986C2 (ru) 2008-04-27
EP1513588A2 (en) 2005-03-16
AR040129A1 (es) 2005-03-16
RU2004138809A (ru) 2005-06-10
US20050222114A1 (en) 2005-10-06
IL165125A0 (en) 2005-12-18
PE20040042A1 (es) 2004-01-31
DE60320786D1 (de) 2008-06-19
BR0311248A (pt) 2005-03-15
UA80703C2 (en) 2007-10-25
HK1072568A1 (en) 2005-09-02
TW200400041A (en) 2004-01-01
WO2003101374A2 (en) 2003-12-11
CA2487293A1 (en) 2003-12-11
PL373295A1 (en) 2005-08-22
WO2003101374A3 (en) 2004-02-26
AU2003246740B2 (en) 2009-01-08
MXPA04011798A (es) 2005-03-31
AU2003246740A1 (en) 2003-12-19
IS7537A (is) 2004-11-18
RS101004A (sr) 2006-10-27
ES2305498T3 (es) 2008-11-01
NO20044903L (no) 2005-02-25
HRP20041127A2 (en) 2005-02-28
EP1513588B1 (en) 2008-05-07
JP2005532336A (ja) 2005-10-27
KR20050005507A (ko) 2005-01-13
ZA200409498B (en) 2006-05-31
ATE394140T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
CN1314701C (zh) 依托孕烯酯
JP4845320B2 (ja) （７α，１１β）−ジメチル−１７β−ヒドロキシ−４−エストレン−３−オンの４−Ｎ−ブチルシクロヘキサン酸エステル及びウンデカン酸エステルの製造方法及びそれらの医学用途
JP2002518514A (ja) テストステロン誘導体
US10351587B2 (en) Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate
CN1298330C (zh) 自我施用的油性溶液的避孕注射
EP1513588B1 (en) Use of new etonogestrel esters
HK1072568B (en) Use of new etonogestrel esters
HK1064678A1 (en) Androgenic 7-substituted 11-halogen steroids
HK1072609B (en) New etonogestrel esters
HK1064678B (en) Androgenic 7-substituted 11-halogen steroids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ORGANON NV

Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP.

Effective date: 20070119

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070119

Address after: Holland

Applicant after: Organon NV

Address before: Holland Arnhem

Applicant before: Akzo Nobel N. V.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050817